Introduction
TNBC, breast cancers, breast cancer
TRIPLE-NEGATIVE BREAST CANCER, BREAST CANCER
Triple-negative breast cancer (TNBC) is pathologically defined as a subgroup of breast cancers that lacks estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression;In recent years, immunotherapy has emerged as a breakthrough for treating TNBC,Studies describing targeted therapies for TNBC have laid the groundwork for precision medicine.Here, we aimed to assess the efficacy and safety of molecular subtyping and genomic sequencing-guided precision therapy for heavily pretreated metastatic TNBC. Our study recruited metastatic TNBC patients who were resistant to the most common chemotherapeutic agents used in breast cancer treatment.